Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.75 -4.0% 42.00 42.00 43.10 42.00 42.00 42.00 161,202 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.1 191

Ekf Diagnostics Share Discussion Threads

Showing 4451 to 4473 of 4500 messages
Chat Pages: 180  179  178  177  176  175  174  173  172  171  170  169  Older
Indicating EKF's Advanced Diagnostic Laboratory (ADL Health) is well placed regarding the trend in hospital outsourcing providing high-quality laboratory services and access to innovative testing -

Quest Diagnostics to Acquire Outreach Lab Services Business of Summa Health

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio

Oct. 5, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Summa Health, a large integrated healthcare delivery system in Ohio, today announced a definitive agreement for Quest to acquire select assets of Summa Health's outreach laboratory services business, referred to as LabCare Plus, in an all-cash transaction.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

The aim of the transaction is to broaden access to innovative, quality and cost-effective laboratory services powering affordable care for communities in Ohio. Under the agreement, Quest's laboratories in Twinsburg, Ohio, and Pittsburgh will provide testing for physicians and patients serviced by LabCare Plus. Summa Health will continue to wholly own and operate its hospital labs providing laboratory services for inpatient and hospital-based outpatient care, along with its anatomic pathology services.

Assuming the transaction's completion, physicians and patients throughout Ohio will benefit from access to Quest's industry-leading and highly innovative test menu, broad health plan coverage, network of patient access sites throughout the state, and lower out-of-pocket costs for many services.

"Laboratory services are a critical and fast-evolving area of healthcare. As the nation's leader, Quest has the expertise, agility and breadth of innovation to deliver the enhanced capabilities that physicians and patients increasingly expect," said Ben Sutton, Chief Strategy Officer and President of Ambulatory Care and Clinical Service Lines for Summa Health. "With this relationship, patients and providers in Ohio will benefit from access to advanced laboratory capabilities supporting better health outcomes."

"Diagnostics provide the insights to deliver healthcare that is both high quality and high value. By helping top health systems like Summa Health optimize their lab strategies, Quest empowers better health and affordable care for more patients," said Steve Rusckowski, Quest Diagnostics Chairman, CEO and President. "We look forward to extending our reach to more communities in Ohio as we strive to build a healthier world."

Summa Health selected Quest Diagnostics following a competitive bid. The parties expect to complete the transaction in the fourth quarter of 2022, subject to customary regulatory approvals. Financial details of the transaction were not disclosed.

As per my 2861 (w price being at 35 then), the then trend reversal has held very well I the face of late market turmoil. Wan - good to see you getting some colour on your cheeks pal. All of them
I note that recently EKF retweeted a Walbrook PR tweet -

EKF diagnostics written up with a "continue to buy" recommendation in Oct edition of the Techinvest Newsletter

"We see considerable potential for growth across all of EKF’s business units and the current strategy seems well conceived."

Aligns with my own thoughts and actions.

EKF's Advanced Diagnostic Laboratory (ADL) website homepage has been updated -

ADL has also launched their comprehensive PreCheck™ Prenatal NIPT national screening webpage -

Recall the following from the Interims -
At the beginning of the year, we signed a strategic partnership agreement with Yourgene Health plc ("Yourgene") to offer a non-invasive prenatal test ("NIPT") service from our accredited US laboratory. We expect this service to launch in October 2022 and we believe this is an exciting growth opportunity.

And from the Strategic partnership agreement with Yourgene -
The adoption for NIPT in the US has accelerated with recent guidelines issued from American College of Obstetricians and Gynaecologists ("ACOG") recommending NIPT to be made available to all pregnant women(1) . As part of the agreement, Yourgene will provide ADL Health with access to YGEN's proprietary reagents and NGS analysis software as part of a technology transfer agreement to enable ADL Health to build a rapid turnaround NIPT service for the US market. Currently, a majority of US NIPT samples are sent to large central testing laboratories, which are costly and experience lengthy lead times . In contrast, the new ADL NIPT service will offer rapid turnaround times as the NIPT workflow can be performed in as little as 48 hours, enabling a competitive response and allowing both EKF and Yourgene to gain traction in this large growing market. According to third party forecasts, the US NIPT market is expected to reach a valuation of USD 2.5 Billion by 2028(2).

Enhancing existing prenatal screening pathways for pregnant women with fast, reliable results while reducing the need for invasive tests and the associated patient stress and anxiety.

Non-Invasive Prenatal Testing

I note the article and comment from the IC below, which has a hold recommendation. One would assume though from the following comment "The company is outperforming compared with pre-pandemic figures, but it must articulate a new direction", that whilst EKF is indeed outperforming, the articulate part was surely made/published prior to the live webcast, because in my view, the management articulated very well indeed regarding the overall business and indeed the new direction.

EKF Diagnostics initiates post-Covid transformation
The company is outperforming compared with pre-pandemic figures, but it must articulate a new direction.
September 20, 2022
By Jennifer Johnson

The IC also refer to "The transition of Contract Manufacturing and Laboratory Services into non-COVID-related revenues is our key challenge." which was stated in the Half Year Report. However, that challenge, when reading only the results, didn't come across in the same way as from the webinar and Interim Presentation, which appeared quite upbeat in terms of the progress to date and the future prospects.

EKF is indeed transitioning though, but to an increasingly sophisticated and diverse global medical diagnostic business, and positioning EKF for very much long-term sustainable growth.

My questions were apparently submitted too late to be considered as part of the Q&A (I was unable to attend the live event).

Interim Results Presentation September 2022 -

EKF is weathering the general market backdrop of supply-chain challenges and inflationary input-cost pressure well thus far, as well as maintaining course in the planned changes and investment in the transition towards their next phase of growth.

A couple of items that recently caught my attention -

Optimized for molecular testing.
Salorn STM is a virucidal, bacteriostatic, Guanidine-free sample collection device, offering highly sensitive antigen testing capabilities.

Salorn STM replaces PrimeStore ATM with a new Triton-X free formula and equivalent activity.

Albeit still accepting orders for research use only.*

5th July 2022
UK Health Security Agency issues report validating PrimeStore MTM inactivation of Monkeypox Virus

PrimeStore Molecular Transport Medium
Product code R13907 (Thermo Fisher Scientific)

Regarding the last point, I have raised a question for the meeting later this afternoon regarding Monkeypox sample collection demand (which will not be in the league of COVID testing), as clearly testing is being performed -

Date Issued: July 15, 2022

The U.S. Food and Drug Administration (FDA) is advising people to use swab samples taken directly from a lesion (rash or growth) when testing for the monkeypox virus. The FDA is not aware of clinical data supporting the use of other sample types, such as blood or saliva, for monkeypox virus testing. Testing samples not taken from a lesion may lead to false test results.

The FDA has said that it does not plan to object to tests being offered that are developed and performed in a CLIA certified laboratory where the tests use PCR technology and lesion swabs, where the tests have been validated and the laboratory notifies the FDA.

Preparation and Collection of Specimens
Updated August 26, 2022

Interesting -

There are lots of recommendations in the American Association for Clinical Chemistry (AACC) and American Diabetes Association (ADA) 2022 draft Consensus Report for Public Comment regarding the use of HbA1c testing in the management and 'diagnosis' of diabetes (Recommendation: Laboratory-based HbA1c testing can be used to diagnose diabetes), which provides food for thought.

The latest proposed 2022 draft guidelines and recommendations for laboratory analysis in diagnosis and management of diabetes also include the following recommendations, including a Glycated Albumin test, a test for which EKF has exclusive distribution rights in the US -

Recommendation: POC HbA1C testing for diabetes screening and diagnosis should be
restricted to FDA approved devices at CLIA-certified laboratories that perform testing of moderate complexity or higher. B (low)

Recommendation: Assays of other glycated proteins, such as fructosamine or glycated albumin, may be used in clinical settings where abnormalities in red cell turnover, hemoglobin variants or other interfering factors compromise interpretation of HbA1c test results, although they reflect a shorter period of average glycemia than HbA1c. GPP

Recommendation: HbA1c cannot be measured in individuals who do not have HbA, e.g., those with homozygous hemoglobin variants, such as HbSS or HbEE; glycated proteins, such as fructosamine or glycated albumin, may be used. GPP

GPP = Good Practice Points (GPPs) are recommendations mostly driven by expert consensus and professional agreement, and are based on the below listed information and/or professional experience, or widely accepted standards of best practice. This category mostly applies to technical (e.g. pre-analytical, analytical, post-analytical), organizational, economic or quality management aspects of laboratory practice. In these cases evidence often comes from observational studies, audit reports, case series or case studies, non-systematic reviews, guidance or technical documents, nonevidence-based guidelines, personal opinions, expert consensus or position statements. Recommendations are often based on empirical data, usual practice, quality requirements and standards set by professional or legislative authorities or accreditation bodies, etc.

ADA/AACC Laboratory Analysis Consensus Report for Public Comment
The American Association for Clinical Chemistry (AACC) and American Diabetes Association (ADA) are posting for public comment a draft of the “Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus” consensus report. The 2022 draft for public comment updates key areas where new evidence has emerged since the 2011 publications.

The public comment period is September 1, 2022 through September 30, 2022. Please email sends e-mail) with comments.

A couple of items that caught my attention -

Our team will be presenting EKF Link and our Diabetes monitoring devices at the event Point of Care Innovations in Bristol, UK. Don't miss out!

Join us at Point of Care Innovations on 20 September 2022 to learn all about the EKF Diagnostics point-of-care range including HbA1c analyzers, glucose analyzers and hemoglobin analyzers for use in the screening, monitoring and diagnosis of patients as well as rapid tests for pregnancy and common infectious diseases.

EKF's point-of-care (PoC) analyzers are designed for use within doctors' surgeries, clinics, hospitals and laboratories to provide fast and accurate results at an affordable price.

By definition, PoC testing is carried out in the presence of the patient allowing open dialogue between them and the practitioner. In this way patients benefit from receiving medical advice during the course of a single visit.

All EKF point-of-care analyzers and consumables are CE marked; there are also CLIA waived products within the portfolio.


Given EKF's range of point-of-care analysers, their growing portfolio provides food for thought regarding the following -

Sep 7, 2022
Pharmacy-Based Testing Sees Growing Legislative, Commercial Momentum
Changing business models and new legislative initiatives are driving point-of-care testing in pharmacies in the wake of the COVID-19 pandemic.

Keith Ashworth-Lord's CFP SDL Free Spirit Fund have this morning issued their monthly factsheet for September, and have this to say about EKF:

"EKF Diagnostics (+11.4%) was the second-best performer following a reassuring trading update at the beginning of the month showing strong growth in the core business. Post update, the investment team visited the Cardiff HQ to meet with Marc Davies, CFO and Gavin Jones, Head of Product Management.

In addition to us passing the haemoglobin and glucose testing with flying colours, we came away impressed by the financial controls put in place by Marc in the relatively short period of time that he has been with the company. The discussion included plans for new product development, US fermentation capacity expansion and the transition away from Covid-related revenues within its contract manufacturing division."

Interview re the Lucica® test which is distributed exclusively by EKF in the USA -

Lucica® Glycated Albumin-L Test for diabetes: Comparisons and Clinical Utility With Shane O’Neill
Published: September 1, 2022
Lucy Lawrence & Tiffany Quinn

In this episode we are joined by Shane O’Neill, director of scientific affairs at EKF Diagnostics. Shane provides an introduction to the glycated albumin (GA) test for intermediate-term glycemic control in diabetic patients.

The GA test is now FDA-cleared and available for use in the United States. It was developed by Asahi-Kasei Pharma of Japan (Lucica® brand) and is a standardized and well-evidenced method for determining glycated albumin levels in the serum.

Shane will also describe why glycemic control is important and discuss the value of the test for glycemic monitoring, outlining its clinical utility and how it compares to other markers of glycemic control, such as hemoglobin A1C and fructosamine.


I note todays RNS re notice of Interim Results and the related live online presentation hosted by Mike Salter (CEO) and Marc Davies (CFO)

Excerpt from an article by Jeff Fischer, President, Longhorn Vaccines and Diagnostics -


A Covid-19 reflection: Incorporating what we’ve learned for improved preparedness
Beyond preparedness policies, we need to think forward to policies that rapidly identify the spread of zoonotic disease to prevent or minimize the impact.

Aug 31, 2022

Evolving toward better preparedness

The silver lining of the situation was that the diagnostics industry was able to respond and flex to the unexpected as we navigated new territory, albeit with some transition bumps and learnings along the way. One important change the industry has made is in expanding our lab capacities. We moved from a pre-pandemic molecular testing rate of 40 to 50 percent to PCR tests now comprising about 70 to 80 percent of volume. We are getting better at maintaining adequate capacity and scaling to meet increased need.

We’re also finding a good balance between test sensitivity versus speed, or rapid testing. Throughout the pandemic, we’ve had to reassess the best test for each particular point in time. Prior to vaccine availability, there was a need to focus on sensitivity because testing was the only tool available to manage the virus. We needed to know with certainty who had Covid-19 so that we could contain the spread and provide early medical care.

As we moved into a vaccine environment and Covid-19 mortality decreased, testing convenience became more important, and with it, a greater uptake of antigen testing. Antigen testing has limitations: it is a less effective containment tool and doesn’t lend itself to accurate caseload reporting. However, it has a role.

As we began to understand the best utility for each type of test, we also discovered their limitations. Antigen tests may not be the best option during a period of rapid and aggressive spread. PCR tests are more accurate, but can’t provide as quick an answer. We discovered that antibody testing was not as helpful as we initially thought it might be and that knowing whether someone had had Covid-19 previously was not as important as knowing whether they were currently carrying the virus.

Additionally, we entered a period of lab innovation that has streamlined and improved processes in long-lasting ways. Covid-19 assays were developed at record speeds and have potential to inform future assay development for other pathogens. At-home test kits, previously subject to a variety of hurdles, have benefited from eager uptake by consumers. Hospital labs developed tightened result turnaround times with the promise of better testing experiences for patients across a range of conditions for years to come.

Transport media that inactivates dangerous pathogens in patient samples now offers improved protection of workers, safer and faster collection and enables temperature-agnostic transport and storage. Solutions such as these have gained an integral place in everyday workflows in the short period of time since they were introduced.

Full article - hTTps://

Cisk...Well we know EKF diversified its customer base so as not to be overly reliant on any one large public sector client (no guarantee that it was Amazon).

Anyway, there is far more to the story than that particular Amazon headline implies, including further potential healthcare acquisitions by Amazon -

Amazon Care and Care Medical are shutting down. Is it really that big a deal?
25th August 2022

A healthcare corporate venture capitalist lauded the “rational decision” that Amazon took in deciding to shut down Amazon Care and Care Medical.

“I love how Amazon keeps trying to crack the employer health market – first with Haven, then with Care and now with One Medical,” said Michael Yang, managing director of OMERS Ventures, the venture arm of the the pension plan for Ontario’s municipal employees, in an email.

The retailer is spending a pretty penny — $3.9 billion — to acquire One Medical though the deal hasn’t closed yet. Yang noted that the San Francisco company has a “far more substantive footprint in the employer market” in comparison with Amazon Care.

In other words, the fact that Amazon is acknowledging failure and moving on, is really not a big deal and doesn’t change the company’s growing ambitions in healthcare. So does the failure even matter?

“Well, healthcare is hard, so we should expect failures but if anything their ambitions are only getting bigger,” Yang said of Amazon. “Whether they kept Care going or shut it down is immaterial. The big deal is One Medical and whatever else they pursue.”

Another healthcare industry player and thought leader agreed.

“[Amazon] previously had a skunk works (Amazon Care and Care Medical) and [it] basically acquired a scaled, clinical operation with the right clinical and regulatory controls in place (One Medical),” said Sachin Jain, CEO of SCAN Health Plan, a Medicare Advantage plan. So, this might just be a fancy way of saying that they’re collapsing that Amazon Care into One Medical,” [Note that the One Medical acquisition is not complete yet.]

In other words, “they are playing to win and realize that building it organically wasn’t going to cut it,” Yang declared, adding that he won’t bet against Amazon despite this setback.

Even after the much-touted Haven floundered, there were similar sentiments: you can’t count Amazon out, you can’t bet against it. But selling healthcare services isn’t like selling books or any other consummable and faster, better, cheaper may not exactly translate to great outcomes.

“I’m not close to the Amazon Care story, but there’s a broader trend in our industry that is replacing specialists with generalist doctors, replacing physicians with nurse practitioners, replacing nurse practitioners with RNs, replacing RNs with community health workers,” Jain pointed out. “And unless you’re kind of founded with really strong clinical DNA, lots of organizations are going to make a lot of mistakes and it’s, you know, it’s not, it’s not clear where that DNA was going to come from, you know, within Amazon.”

Perhaps this is why Amazon isn’t exactly stopping with the acquisition of One Medical. Reportedly, it is also one of the suitors bidding for Signify Health that is a value-based care company with a market cap of $6.6 billion. Based in Dallas, Signify Health is powering in-home health services, the next place rife with opportunity in healthcare. Sitting within Signify Health is also another company it bought called Caravan, which supports accountable care organizations. In fact, Caravan has within its client base more than 200 health systems and 100 Federally Qualified Health Centers with more than 10,000 primary care providers that collectively manage over 500,000 patients, according to a February MedCity News article.
Full article - hTTps://

Amazon to close US telehealth service as it shifts sector ambitions
Tech group seeking more access to corporate employees in bid to gain foothold in $4tn healthcare market
25th August 2022

Analysts said Amazon Care’s closure, which will come at the end of the year, should not be seen as a retreat on its efforts to gain a foothold in the $4tn US healthcare sector. “This is not a sign of failure by any means,” said Natalie Schibell at Forrester Research. “It’s a strategic move.”

Amazon’s decision comes after its recent agreement to acquire One Medical, a large network of primary care providers, for $3.9bn — its largest deal in the healthcare space.

Amazon’s ambitions in healthcare have been years in the making, and are set to intensify under the leadership of Andy Jassy, who replaced Jeff Bezos as chief executive last year.

Ultimately, Amazon’s M&A activity points to it assembling the building blocks for a large health service offering “value-based care”, said Rebecca Springer, a senior analyst covering healthcare at PitchBook. The term describes a business model where health providers earn income based on patient outcomes — how well the patient is — versus merely providing treatments.

Full article, - hTTps://


Impact on EKF?

I feel this is wider markets led. However a firm close below 36 (if and when it happens) will invite a completely neutral stance on this.
48 captured intraday chaps. Didn't take that long did it. First milestone out of the way.
Doing what's it meant to be - 48 to be captured v soon. Once we have that in the bag, 63 is the next stop.
INSP shares jump soon
Allowing for a bit of time to price consolidating around 48 area, one should then expect 63 as the next stop after that. On the balance of odds.
Yes, interesting and encouraging positive price action yesterday.

In my view, there is quite a lot of positive development to report, which the Trading Update indeed implied. I am therefore looking forward to EKF reporting their interim results more fully in September.

Following the related healthcare and diagnostic sectors as I do, I am also very much encouraged regarding EKF's prospects as we enter the next chapter of their growth phase.

Glad to see a few have finally got some colour on their cheeks. All four of them....As you can see chaps there is a time to be long and a time to be short. And another one to get back long again. 48 is next.
Looks like a tipsheet.
8 trades before 14 22 and 61 since.

Very encouraging price action.
48 is next immediate milestone if we close firmly above 41.
Chat Pages: 180  179  178  177  176  175  174  173  172  171  170  169  Older
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221130 05:08:02